On May 4th and 5th, 2022 we had the Kick-off Meeting of our project that is funded by an European Innovation Council (EIC) Transition Grant. The consortium members formed by CRG, SINTEF, Inveniam Group and INSERM met for the first time in person at the Centre for Genomic Regulation (CRG). The TAONas-LUAD project aims to develop an innovative therapy based on the use of Antisense Oligonucleotides (AONs) that regulate alternative splicing (AS) to target a pro-proliferative protein isoform observed in the vast majority of Lung adenocarcinomas (LUAD) tumors. The technology developed by Juan Valcarcel and Jordi Hernández PhD MBA at CRG will be adapted for non-viral lipid nanoparticles delivery by Dr. Sven Even Borgo’s group from SINTEF and validated in vivo using lung cancer xenographs models at Dr. Antonio Maraver’s lab from INSERM.
The Kick-off meeting left everyone feeling inspired by the rewarding scientific discussions. We are excited about the challenge of making this 4-year project a reality, bringing TAONas-LUAD technology closer to the market and closer to being a future therapy for lung cancer patients!